SWOG S1500

Primary Category:

Treatment Protocols

Disease Category:

Renal, Renal Metastatic

Status:

Closed

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

 

NCT#02761057

Effective December 15th, 2019, study S1500 will be permanently closed to accrual.